Compare Stocks

→ The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMS Adamas Pharmaceuticals	$8.22	$8.17	$4.02 ▼ $9.15	$376.37M	2.82	692,487 shs	N/A
CYCN Cyclerion Therapeutics	$2.83 -7.2%	$3.10	$1.75 ▼ $6.75	$7.67M	1.84	3,211 shs	717 shs
MLND Millendo Therapeutics	$3.44 +0.6%	$4.00	$0.92 ▼ $16.95	$65.51M	0.48	1.52 million shs	652,486 shs
MRKR Marker Therapeutics	$4.40 -0.7%	$4.27	$0.76 ▼ $9.68	$39.16M	1.5	20,635 shs	9,988 shs
OASM Oasmia Pharmaceutical AB (publ)	$0.02	$1.46	$0.94 ▼ $5.70	$1.50M	0.96	98,414 shs	N/A

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMS Adamas Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CYCN Cyclerion Therapeutics	-6.73%	-12.06%	-9.18%	-19.71%	-52.18%
MLND Millendo Therapeutics	+5.56%	+2.09%	-6.04%	-13.20%	+49.34%
MRKR Marker Therapeutics	+5.73%	+0.68%	-9.78%	+6.22%	+381.52%
OASM Oasmia Pharmaceutical AB (publ)	0.00%	0.00%	0.00%	0.00%	-60.00%

$25,000 into $109,616 in two months? (Ad)

Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…

Go here to watch the most recent trading workshop video at no charge.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMS Adamas Pharmaceuticals	$74.46M	5.05	N/A	N/A	($0.47) per share	-17.49
CYCN Cyclerion Therapeutics	$1.62M	4.73	N/A	N/A	$4.62 per share	0.61
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
MRKR Marker Therapeutics	$3.31M	11.83	N/A	N/A	$1.58 per share	2.78
OASM Oasmia Pharmaceutical AB (publ)	$220K	6.82	N/A	N/A	$0.63 per share	0.03

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMS Adamas Pharmaceuticals	-$57.40M	-$1.70	N/A	N/A	N/A	-71.11%	N/A	-42.96%	N/A
CYCN Cyclerion Therapeutics	-$5.26M	-$5.51	N/A	∞	N/A	N/A	-111.79%	-74.10%	5/9/2024 (Estimated)
MLND Millendo Therapeutics	-$36.41M	N/A	0.00	∞	N/A	N/A	-91.03%	-72.44%	N/A
MRKR Marker Therapeutics	-$8.24M	N/A	0.00	∞	N/A	-142.62%	-39.89%	-25.45%	5/21/2024 (Estimated)
OASM Oasmia Pharmaceutical AB (publ)	-$18.95M	N/A	0.00	∞	N/A	-8,633.64%	-43.94%	-28.92%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A	N/A
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMS Adamas Pharmaceuticals	21.25	4.53	4.17
CYCN Cyclerion Therapeutics	N/A	3.85	3.85
MLND Millendo Therapeutics	N/A	6.39	6.39
MRKR Marker Therapeutics	N/A	5.57	5.57
OASM Oasmia Pharmaceutical AB (publ)	N/A	0.80	0.73

Ownership

Institutional Ownership

Company	Institutional Ownership
ADMS Adamas Pharmaceuticals	69.97%
CYCN Cyclerion Therapeutics	75.62%
MLND Millendo Therapeutics	N/A
MRKR Marker Therapeutics	22.39%
OASM Oasmia Pharmaceutical AB (publ)	0.11%

Insider Ownership

Company	Insider Ownership
ADMS Adamas Pharmaceuticals	18.90%
CYCN Cyclerion Therapeutics	13.10%
MLND Millendo Therapeutics	N/A
MRKR Marker Therapeutics	24.10%
OASM Oasmia Pharmaceutical AB (publ)	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMS Adamas Pharmaceuticals	138	45.79 million	37.13 million	Optionable
CYCN Cyclerion Therapeutics	1	2.71 million	2.36 million	No Data
MLND Millendo Therapeutics	12	19.04 million	N/A	Not Optionable
MRKR Marker Therapeutics	8	8.90 million	6.76 million	Not Optionable
OASM Oasmia Pharmaceutical AB (publ)	57	74.97 million	N/A	Not Optionable

MRKR, CYCN, ADMS, MLND, and OASM Headlines

Source	Headline
	Lipigon Pharmaceuticals AB LPGO morningstar.com - March 23 at 12:53 AM
	LSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call Transcript gurufocus.com - March 6 at 9:00 AM
	Oasmia Pharmaceutical AB (publ) - Special Call Transcript gurufocus.com - March 6 at 9:00 AM
	Resurs Holding AB (publ) (RESURS.ST) finance.yahoo.com - February 8 at 12:32 AM
	QuiaPEG Pharmaceuticals Holding AB QUIA morningstar.com - January 6 at 5:30 PM
	Newbury Pharmaceuticals AB (NEWBRY) investing.com - November 29 at 2:08 AM
	Dentsu Creative bags mandate for Torrent Pharmaceuticals’ Shelcal & Unienzyme bestmediainfo.com - September 26 at 1:06 AM
	Lipigon Pharmaceuticals AB (LPGO) investing.com - September 14 at 9:09 AM
	Speqta publ AB (SPEQT) investing.com - August 25 at 9:50 PM
	PRXXF Paradox Interactive AB (publ) seekingalpha.com - August 25 at 9:29 AM
	Notice of annual general meeting in Alzinova AB (publ) privataaffarer.se - April 25 at 8:37 AM
	Report from Annual General Meeting 2023 of PowerCell Sweden AB (publ) privataaffarer.se - April 21 at 8:26 PM
	Notice of Annual General Meeting 2023 in Enzymatica AB (publ) (2) europapress.es - April 2 at 9:53 AM
	OXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2M seekingalpha.com - February 26 at 11:56 PM
	US regulators clear way for more monkeypox vaccine shipments starherald.com - July 14 at 11:12 AM
	PRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE (MFN) avanza.se - March 24 at 6:47 AM
	Oasmia expands R&D ability with planned laboratory upgrade privataaffarer.se - March 17 at 8:40 AM
	Orexo appoints Fredrik Järrsten as new CFO stockhouse.com - March 11 at 3:47 AM
	Notice of extra general meeting in Terranet AB finanznachrichten.de - November 29 at 10:24 AM
	Pet Cancer Therapeutics Market – Know-How Industry to Experience Positive Growth \| robust CAGR of 7.7% over the forecast period (2017 – 2025). medgadget.com - September 17 at 2:52 AM
	Veterinary Cancer Therapeutics Market Segmentation, Size Analysis, Key Players Forecast To 2027 openpr.com - July 28 at 7:04 PM
	Fancy Wood Industries PCL (FANCY) investing.com - July 22 at 7:07 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adamas Pharmaceuticals

NASDAQ:ADMS

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Cyclerion Therapeutics

NASDAQ:CYCN

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Millendo Therapeutics

NASDAQ:MLND

As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.

Marker Therapeutics

NASDAQ:MRKR

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer. Marker Therapeutics is headquartered in Houston, Texas.

Oasmia Pharmaceutical AB (publ)

NASDAQ:OASM

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial